CytoDyn to Host Investor Webcast

VANCOUVER, Wash., Oct. 15, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple solid-tumor oncology indications, including colorectal cancer (“mCRC”) and metastatic triple-negative breast cancer (“mTNBC”), today announced it will host an investor webcast on October 19, 2026, at 1 p.m. PT, to pro